MedTrace Logo

GFRα4 CAR T Cells in MTC Patients

NCT04877613 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-07-03

No results posted yet for this study

Summary

This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells expressing a single-chain scFv targeting GFRα4 with tandem TCR/CD3ζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as "CART-GFRa4 cells") in patients with incurable medullary thyroid cancer (MTC).

Conditions

  • Metastatic Medullary Thyroid Cancer
  • Recurrent Thyroid Gland Medullary Carcinoma

Interventions

DRUG

single dose of CART-GFRa4 cells

Intravenous infusion of lentiviral transduced autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity towards GFRa4 with fludarabine and cyclophosphamide.

DRUG

Fludarabine

Lymphodepletion

DRUG

Cyclophosphamide

Lymphodepletion

Sponsors & Collaborators

Principal Investigators

  • Roger Cohen, MD · University of Pennsylvania

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-19
Primary Completion
2039-06-01
Completion
2039-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04877613 on ClinicalTrials.gov